Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, May 6 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS) announced
today that it will report financial results for the first quarter 2009 ended
March 31, 2009, on Friday, May 15, 2009. TSO3 will host a conference call at
10:30 A.M. (ET) the same day.
Analysts and institutional investors are invited to participate. The
numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3424
(Toronto area) or the toll-free number 1-800-594-3790. Journalists and other
interested parties may listen to the live Webcast of the Conference Call
accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived
for 90 days.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers
in the hospital environment.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
TSO3's STERIZONE(R) 125L Sterilizer is cleared for commercialization by
the US Food and Drug Administration and by Health Canada for sterilization of
metal and heat sensitive instruments and devices with diffusion-restricted
spaces, such as the hinged portion of haemostats, forceps and scissors and
rigid endoscopes having a single stainless steel lumen as small as 0.9 mm
internal diameter and 485 mm long is in commercialization phase for this first
product since 2006.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Marc Boisjoli, Chief Financial Officer, (418)
651-0003, ext. 228, firstname.lastname@example.org; Frédéric Tremblay, (514) 658-8033,
email@example.com; Source: TSO(3) Inc.